Updated: October 28, 2020

We recognize that this may be a challenging and stressful time, especially if you are a patient managing a serious illness. As the COVID-19 global pandemic continues to evolve, we are committed to doing everything we can to deliver for patients, to keep our staff and their families safe, and to help the communities where we live and work reduce the number of people exposed to the virus.

Amgen’s COVID-19 Priorities

  • Ensuring the safety and well-being of our 23,000+ Amgen employees around the world
  • Continuing to serve patients – those currently on Amgen medicines and those that stand to benefit from potential new medicines in our pipeline
  • Contributing our therapeutic antibody and immunology expertise to the fight against COVID-19
  • Lending a helping hand in the communities where we live and work

Frequently Asked Questions

PATIENTS

Where should I go if I have a COVID-19 question about an Amgen medicine I’m taking?

  • If you have questions about your Amgen medication, you can reach us via phone in the U.S. at 1-800-772-6436. If you live outside of the U.S., local contact information by country can be found here. If you have any questions about your treatment plan because of concerns about COVID-19, it is important to consult with your doctor.

Where can I find Amgen's product websites?

Where can I find more information if I'm in an Amgen Clinical Trial?

  • With the situation around COVID-19 being so fluid and dynamic, we respectfully request that you contact your Clinical Site Investigator (Medical Doctor) for guidance with respect to the site’s current availability to receive your visit, study procedures, treatment (if applicable) or any safety issues.
  • Study procedures are being implemented consistent with recent guidance from regulators to maintain patient safety and study data integrity.
  • Medical conferences and journals are being engaged to ensure continued dissemination of important data in a timely manner.

See information about Amgen’s Forward-Looking Statements here.

What can I do if alcohol wipes are unavailable that are required for injection?

  • During the COVID-19 pandemic, cleaning with soap and water may be an alternative. Our Instructions for Use (IFU) provides guidance that alcohol wipes are preferred. However, if you are out of alcohol wipes, please consult with your healthcare provider.

Can I receive my medication without going to a pharmacy?

  • Many pharmacies are now offering mail order, some even do it free of charge. Please call your pharmacy to see what options are available to you.
  • Our teams are working to address continuity of care issues and exploring novel solutions such as alternate sites of care, mobile nurse administered injections and prescription fills at specialty and retail pharmacies. We are also working with policy makers and advocacy organizations to address treatment challenges in this environment.

What do I do if I am on an Amgen medicine and recently lost my health insurance?

  • You may have questions about what other insurance options may be available to you. You can learn more about alternate health coverage options by reviewing our Resource Guide.
  • The Amgen Safety Net Foundation (ASNF) may be able to help. To support U.S. patients who may be newly uninsured due to a COVID-19 related job loss, ASNF is providing temporary enrollment to those who meet eligibility requirements.
  • You can learn more about this temporary enrollment visit www.amgensafetynetfoundation.com/covid-19.html or by calling 1-888-762-6436.
  • ASNF is a nonprofit patient assistance program established in 2001, sponsored by Amgen. ASNF was designed to assist patients who have a financial need and are uninsured or the insurance plan excludes the Amgen medicine. ASNF supports qualifying residents of the U.S. and its territories.

Supply

Is there any interruption to the supply of medicines based on COVID-19?

  • We continued to have success in supplying “every patient, every time” with our medicines. (Updated: July 28, 2020)

See information about Amgen’s Forward-Looking Statements here.

Research and Development

What is Amgen doing about COVID-19 from an R&D standpoint?

  • Amgen is working collaboratively with other biotechnology companies, academic institutions, the Administration and other government research entities to identify effective treatments for COVID-19 as quickly as possible:
    • Amgen is participating in the National Institutes of Health (NIH) and the Foundation for the NIH’s (FNIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership, as well as the COVID R&D Alliance, a group of more than 20 of the world’s leading biopharmaceutical and life sciences companies working to speed the development of potential therapies, novel antibodies, and anti-viral therapies for COVID-19 and its related symptoms.
    • Otezla® (apremilast), an oral treatment approved in more than 50 countries for inflammatory diseases such as psoriasis and psoriatic arthritis, will be investigated as a potential immunomodulatory treatment for hospitalized patients with COVID-19 in platform trials, including the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and Adaptive Learning) and REMAP-COVID, a sub-study of REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia). Although some treatments have received authorization for emergency use, there are no approved treatments for COVID-19. Otezla inhibits the activity of phosphodiesterase 4 (PDE4), an enzyme found in inflammatory cells in the human body. By inhibiting PDE4, Otezla is thought to modulate the production of inflammatory cytokines and other mediators.
    • In our pursuit of therapeutic antibodies, the Company is focusing our efforts on the development of therapeutic antibodies against targets other than the SARS-Cov2 receptor binding domain, with the goal being to develop an antibody complementary to the first-generation therapies.

See information about Amgen’s Forward-Looking Statements here.

MEDICAL PROFESSIONALS

Where do I go to report an adverse event or contact a medical information professional?

  • For product questions, to report an adverse event or safety-related issue, or to report a quality issue with a product or device, call +1 800-772-6436 (800-77-AMGEN) or +1 805-447-3505. Local contact information by country can be found here.
  • U.S. healthcare professionals can also visit www.amgenmedinfo.com.

My patient recently lost their job and insurance due to COVID-19. Where can I direct them?

  • The Amgen Safety Net Foundation (ASNF) may be able to help. To support U.S. patients who may be newly uninsured due to a COVID-19 related job loss, ASNF is providing temporary enrollment to those who meet eligibility requirements.
  • Your patient can visit www.amgensafetynetfoundation.com/covid-19.html or by calling 1-888-762-6436.

EMPLOYEES AND COMMUNITY

What is Amgen doing to limit the spread of COVID-19 on its campuses?

  • Since March 16, all employees who were able to work from home have been doing so. This includes staff at our corporate headquarters in Thousand Oaks, CA.
  • Our field staff in the U.S. have moved to an approach that ensures continuity of support through a blend of virtual and in-person engagements. This approach allows us to have safe interactions while adapting to the dynamic situation of COVID-19.
  • Amgen has suspended international business travel and limited domestic travel in the U.S., including attendance at medical congresses, conferences and other large events.
  • Enhanced cleaning procedures and visitor screenings were implemented at all Amgen locations since the beginning of the pandemic, and we are taking measures at our sites to ensure physical distancing. We will also conduct temperature screenings and COVID-19 testing, where permitted under local requirements.

See information about Amgen’s Forward-Looking Statements here.

How is Amgen returning employees to the workplace and field and what safety measures are you following to maintain the safety of the workplace?

From the beginning, our top priority has been ensuring the health and safety of our people. Close to 20% of employees have been working onsite across the globe and we’ve learned from that, giving us confidence we can keep additional people healthy and safe as they return. We will return more staff to the workplace and field when it’s safe to do so. The timing and pace will be different for every location based on local conditions. We are taking the following measures to maintain the safety of our workplaces:

  • Occupancy limits to allow for physical distancing
  • Continued business travel and external meeting attendance restrictions
  • Personal protective equipment
  • Temperature screening
  • COVID-19 testing and contact tracing
  • Daily enhanced cleaning of high-touch areas
  • Employees instructed to clean workstations before and after use
  • Behavior reminders… stay home when unwell or when caring for someone who is unwell, wash hands frequently

What types of support and assistance is Amgen providing for its employees?

Financial Support

  • We have committed to pay continuity for employees and will assess the duration of that commitment as the situation evolves.
  • We are providing staff working from home in the U.S. and Puerto Rico a monthly stipend for home broadband Internet access along with an allowance to purchase any necessary home office equipment.

Working from Home Assistance

  • We have set up an internal website dedicated to COVID-19 for employees to review updates, video messages from leadership, podcasts, access to training, and frequently asked questions.
  • We have launched an additional teleconferencing platform globally with dedicated technical support.
  • Ongoing online training and development is being used by thousands of employees.

Employee Wellness Resources

  • We have launched a virtual health and wellness program for all Amgen team members with an emphasis on work-at-home strategies.
  • We have implemented a virtual workout, nutrition, and yoga app offering for all of our Amgen team members around the world with hundreds of regionally appropriate online programs free of charge.
  • We are offering mental health resources, including virtual coaching, therapy sessions, meditation and mindfulness programs.
  • We are providing manager resources, such as resilience training, to help our leaders assist their teams through this period of dynamic change.
  • Our largest medical plan is offering telemedicine visits for all illnesses with no deductibles or co-insurance for 90 days to encourage the safety of our team members, their families and healthcare providers.

See information about Amgen’s Forward-Looking Statements here.

Is Amgen or the Amgen Foundation doing anything in the community in response to COVID-19?

  • Amgen and the Amgen Foundation have made an initial commitment of up to $12.5 million in COVID-19 relief funds to support emergency response efforts in Amgen’s U.S. and international communities, patient-focused organizations that are mounting their own response efforts, and international relief efforts by Direct Relief and International Medical Corps. The Amgen Foundation is also matching donations made by our employees worldwide who wish to contribute their own funds to the relief efforts. Read more here.

    These funds are being deployed as quickly as possible and include:
    • Senior Concerns, an adult day care center located in Amgen’s headquarter location of Thousand Oaks, California, received a $100,000 grant to ensure that their critical meals delivery programs to affected seniors could continue despite the collapse of their income generating programs. This is part of a $2 million commitment that the Amgen Foundation announced going towards more than a dozen organizations in Los Angeles and Ventura counties, which is within the general vicinity of Amgen’s global headquarters in Southern California.
    • In Louisville, Kentucky, $100,000 will be going to the One Louisville COVID-19 Response Fund that will rapidly deploy resources to households, businesses, and community-based organizations (nonprofit organizations) working at the frontlines of the Louisville-area coronavirus outbreak. The goal of this fund is to attract and provide financial assistance to help communities, households, and businesses who are disproportionately impacted by the virus and its economic consequences. Read more here.
    • In Rhode Island, $500,000 will be going to the Rhode Island COVID-19 Response Fund which is being jointly managed by the Rhode Island Foundation and the United Way. The COVID-19 Response Fund grants will be awarded to support nonprofit organizations providing direct assistance to Rhode Islanders with financial need or demonstrable hardship resulting from COVID-19 and not otherwise covered by other resources. This may include organizations that supply basic needs to Rhode Islanders, including but not limited to, food, relief from rent and other household expenses, and access to healthcare. Read more here.
    • In greater Washington DC, $100,000 will be going to community-based non-profit organizations working at the frontlines on relief efforts. These include a $25,000 grant to the United Way of the National Capital Area’s emergency assistance fund, $25,000 to the Manna Food Center in Montgomery, MD, $12,500 to the Capital Area Food Bank and $12,500 to So Others Might Eat (SOME) in Washington, DC, and $25,000 to the Community Foundation for Northern Virginia in Oakton, VA. Read more here.
    • In South San Francisco, $500,000 will be going to Silicon Valley Community Foundation (SVCF), which is leading multiple efforts with Bay Area philanthropic, government, and corporate partners to support those most affected by COVID19. Read more here.
    • In Tampa, Florida, we donated an additional $250,000 to the United Way Suncoast COVID-19 Response & Recovery Fund.
    • In New Jersey, where we have a new site, we donated $100,000 to the New Jersey Pandemic Relief Fund.
    • Also earmarked is $2 million to support patient-focused organizations in the U.S. that are mounting their own response efforts. One of these is the Leukemia & Lymphoma Society (LLS), which is providing eligible blood cancer patients with a $250 stipend to help with non-medical expenses, such as food, housing, utilities, transportation and other needs. Amgen’s contribution to LLS will help 1,000 patients in need.
  • Amgen has also expanded their Staff Volunteer program to allow medically trained staff the opportunity to take voluntary leaves to support COVID-related work in their communities.
  • Additionally, the Amgen Foundation is a proud sponsor of two on-line learning platforms – Khan Academy and LabXchange – that are providing free world-class educational content to millions of students around the world at a time when many are no longer going to school.
    • In January, the Amgen Foundation and Harvard’s Faculty of Arts and Sciences launched LabXchange, a free online science education platform that provides users access to personalized instruction, virtual lab experiences and networking opportunities across the global scientific community. As the founding sponsor, the Amgen Foundation awarded $11.5 million in grant funding to Harvard to deepen the impact of this new online learning platform across the globe.
    • The Amgen Foundation is the founding biology partner of the Khan Academy, a leading innovative and effective educational technology platform with over 70 million registered users across the globe. In July, the Amgen Foundation renewed a $3 million grant to Khan Academy to support several key learning initiatives, including virtual biology lessons; partnerships with school districts facing budget shortfalls; and a collaboration with LabXchange.
    • Free online learning programs supported through both of these deep relationships are available to help students continue their science education during school closures, and can be accessed via the LabXchange and Khan Academy’s online learning websites.

    See information about Amgen’s Forward-Looking Statements here.

GENERAL INFORMATION

Where should I go to find general information about COVID-19?